Analysts await Incyte Corporation (NASDAQ:INCY) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $0.15 EPS, up 173.33% or $0.26 from last year’s $-0.11 per share.

At the moment 17 analysts are watching Incyte Corporation (NASDAQ:INCY), 7 rate it “Buy”, 9 “Outperform”, 1 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 14 analysts have a mean sales target of 230.68 million. For the quarter ending Sep-16, 14 analysts have a mean sales target of 242.74 million whilst for the year ending Dec-16, 17 analysts have a mean target of 1,007.36 million.

In terms of earnings per share, 14 analysts have a 0.01 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 14 analysts have a -0.01 EPS mean target and for the quarter ending Sep-16 there are 16 estimates of 0.19 EPS.

The biggest institutional shareholders in Incyte Corporation include Wellington Management Company LLP which owns 25 million shares in the company valued at $1.85 B million. Baker Bros Advisors Llc is the second biggest holder with 23 million shares currently valued at 1.73 B million whilst T. Rowe Price Associates, Inc. has 19 million shares valued at 2.07 B million.

Total shares held by institutions as of the most recent company filings are 188,586,439 with a reported 24,619,534 bought and 13,138,406 sold. These holdings make up 91.88% of the company’s outstanding shares.

Currently insiders hold 2,758,604 shares in the business which makes up 1.47% of shares. The biggest holder currently is Mr. Roy A. Whitfield who owns 662,832 shares (0.35% of those outstanding), whilst Mr. Herve Hoppenot holds 360,203 (0.19% of shares outstanding) and Dr. Paul A. Friedman,M.D. holds 297,518 (0.16% of shares outstanding).

The stock increased 0.40% or $0.28 during the last trading session, hitting $77.90. Incyte Corporation (NASDAQ:INCY) has fallen 35.89% over the past 6 months and is downtrending.